CRESCENT BIOPHARMA, INC. — Director's Dealing 2016

Jul 6, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2016-07-01

Reporting Person: Thackray Helen M. (VP Clinical Development, CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-01	Common Stock	S	5068	$7.40	Disposed	179547	Direct
2016-07-05	Common Stock	S	10136	$7.01	Disposed	169411	Direct
2016-07-06	Common Stock	S	6796	$6.68	Disposed	162615	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $7.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $7.49, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.92, inclusive.